Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma.

@article{Cruz2001IbandronateDB,
  title={Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma.},
  author={Juliana C Cruz and M. Sabes Alsina and Fiona J. Craig and Toshiyuki Yoneda and Judith L. Anderson and M. D. Dallas and Garson David Roodman},
  journal={Experimental hematology},
  year={2001},
  volume={29 4},
  pages={441-7}
}
The benefits of bisphosphonate therapy for multiple myeloma bone disease have been clearly documented. However, the effects of bisphosphonates on the osteoclast stimulatory activity (OSA) that is present in the marrow of patients with multiple myeloma, even before the bone disease is detectable, are unknown. Therefore, we examined the effects of ibandronate (IB) treatment prior to the development of bone disease in a murine model of human myeloma. Sublethally irradiated severe combined… CONTINUE READING
8 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-8 of 8 extracted citations

Similar Papers

Loading similar papers…